Authors: Yang Shiqi, Sun Xiaodong
Cite as Chin J Exp Ophthalmol, 2018,36(3): 236-240.
Abstract [Download PDF] [Read Full Text]
As a progressive chronic disease, age-related macular degeneration (AMD) is the leading cause of blindness worldwide.However, current therapy for AMD shows a dramatic breakthrough.More and more patients with AMD undergo intravitreous injection of anti-vascular endothelial growth factor A (VEGF-A) regimen, which has been demonstrated a beneficial therapeutic treatment to improve visual acuity in a short period.The long-term outcomes have come into focus considering prolonged treatment cycle and follow-up period.The long-term outcomes and safety of anti VEGF-A will be reviewed in this article contributing to investigate the causes influencing prognosis of visual acuity after anti VEGF-A treatment.
Age-related macular degeneration, wet; Choroidal neovascularization; Vascular endothelial growth factor; Long-term outcomes
Department of Ophthalmology, Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China
(Read 92 times, 1 visits today)